Novel CAR-T Cell Therapy Shows Promise for Pediatric Diffuse Midline Glioma Treatment
1. Approximately 88% of patients with GD2-positive diffuse midline glioma or other progressive CNS...
Read More
Oncology
Dose-dense adjuvant therapy with epirubicin and cyclophosphamide effective for breast cancer
1. Dose-dense adjuvant chemotherapy involving sequential epirubicin/cyclophosphamide and docetaxel...
Read More
#VisualAbstract Bilateral Masectomy Reduces Risk of Contralateral Breast Cancer But Does Not Reduce the Breast Cancer Mortality Rate
Click here to read this study in the NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
#VisualAbstract: Blinatumomab Improves Survival in MRD-Negative Acute Lymphoblastic Leukemia in Adults
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No...
Read More
TKI With or Without SRS for Brain Metastases From EGFR/ALK Mutated NSCLC
1. Median overall survival was 41 months in the TKI-only group vs 40 months in the TKI-SRS group,...
Read More
Sintilimab improves survival in advanced non-metastatic nasopharyngeal carcinoma
1. Patients in the sintilimab group reported a significantly greater event-free survival at 36...
Read More
Hormone-modulating therapy decreased risk of dementia in breast cancer patients
1. In a retrospective cohort study of women newly diagnosed with breast cancer, use of hormone...
Read More
#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma
Click here to read this study in Lancet Oncology. ©2024 2 Minute Medicine, Inc. All rights...
Read More
Vimseltinib may be promising in treating symptomatic tenosynovial giant cell tumour
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most...
Read More
Multi-Organ Immune-related Adverse Events from Immune Checkpoint Inhibitors
1. Co-occurrences could be clustered together into 7 clusters based on the predominant organ...
Read More
Tisotumab Vedotin as Second or Third-Line Therapy for Recurrent Cervical Cancer
1. Median overall survival was 11.5 months in the tisotumab vedotin group and 9.5 months in the...
Read More
Immunotherapy-Based Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2....
Read More
Poor sleep and elevation of liver function biomarkers may be predictive of liver cancer
1. Unhealthy sleep, as well elevations of liver enzymes and decreased levels of albumin and liver...
Read More
Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions
1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab...
Read More
Amivantamab and Lazertinib in Untreated EGFR-Mutated Advanced NSCLC
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the...
Read More
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction...
Read More
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced NSCLC
1. Patients with no biochemical or radiographic evidence of progressive disease had a median...
Read More
Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
1. Treatment with osimertinib significantly improved progression-free survival, compared to...
Read More
Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colon Cancer
1. No disease recurrences were observed during the median follow-up time of 26.2 months. 2....
Read More
Quantifying the reduction of primary breast cancer associated with exercise
1. Across a follow-up period of approximately 5 years, there was a non-linear relationship between...
Read More